1. Home
  2. PODD vs NTRA Comparison

PODD vs NTRA Comparison

Compare PODD & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • NTRA
  • Stock Information
  • Founded
  • PODD 2000
  • NTRA 2003
  • Country
  • PODD United States
  • NTRA United States
  • Employees
  • PODD N/A
  • NTRA N/A
  • Industry
  • PODD Medical/Dental Instruments
  • NTRA Medical Specialities
  • Sector
  • PODD Health Care
  • NTRA Health Care
  • Exchange
  • PODD Nasdaq
  • NTRA Nasdaq
  • Market Cap
  • PODD 17.2B
  • NTRA 18.4B
  • IPO Year
  • PODD 2007
  • NTRA 2015
  • Fundamental
  • Price
  • PODD $246.80
  • NTRA $148.08
  • Analyst Decision
  • PODD Buy
  • NTRA Strong Buy
  • Analyst Count
  • PODD 17
  • NTRA 17
  • Target Price
  • PODD $294.65
  • NTRA $176.65
  • AVG Volume (30 Days)
  • PODD 878.5K
  • NTRA 1.6M
  • Earning Date
  • PODD 05-08-2025
  • NTRA 05-08-2025
  • Dividend Yield
  • PODD N/A
  • NTRA N/A
  • EPS Growth
  • PODD 96.55
  • NTRA N/A
  • EPS
  • PODD 5.78
  • NTRA N/A
  • Revenue
  • PODD $2,071,600,000.00
  • NTRA $1,696,911,000.00
  • Revenue This Year
  • PODD $20.53
  • NTRA $15.33
  • Revenue Next Year
  • PODD $17.42
  • NTRA $18.50
  • P/E Ratio
  • PODD $42.67
  • NTRA N/A
  • Revenue Growth
  • PODD 22.07
  • NTRA 56.75
  • 52 Week Low
  • PODD $160.19
  • NTRA $83.13
  • 52 Week High
  • PODD $289.46
  • NTRA $183.00
  • Technical
  • Relative Strength Index (RSI)
  • PODD 42.59
  • NTRA 50.83
  • Support Level
  • PODD $241.54
  • NTRA $125.38
  • Resistance Level
  • PODD $258.00
  • NTRA $152.66
  • Average True Range (ATR)
  • PODD 13.13
  • NTRA 8.82
  • MACD
  • PODD -0.61
  • NTRA 1.47
  • Stochastic Oscillator
  • PODD 34.84
  • NTRA 82.19

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: